相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trial sequential analysis: adding a new dimension to meta-analysis
A. Shah et al.
ANAESTHESIA (2020)
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence
Janneke C. Ham et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis
Ashley Lau et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
Tania Crombet Ramos et al.
FRONTIERS IN ONCOLOGY (2020)
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
Adileh Ayati et al.
BIOORGANIC CHEMISTRY (2020)
EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations
Hina S. Rehmani et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J-P Machiels et al.
ANNALS OF ONCOLOGY (2020)
Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials
Xiaoxia Tang et al.
JOURNAL OF ONCOLOGY (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Immunotherapy for head and neck cancer: Recent advances and future directions
John D. Cramer et al.
ORAL ONCOLOGY (2019)
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer
Peter H. Ahn et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis
Yapin Su et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
P. Bossi et al.
ANNALS OF ONCOLOGY (2017)
Current Role of Dacomitinib in Head and Neck Cancer
Olgun Elicin et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Afatinib in squamous cell carcinoma of the head and neck
Pol Specenier et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
Lori J. Wirth et al.
ORAL ONCOLOGY (2016)
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
Paolo Bossi et al.
ONCOTARGET (2016)
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma
Vandana Singh Kushwaha et al.
CANCER BIOLOGY & THERAPY (2015)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno et al.
ORAL ONCOLOGY (2015)
Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights
Gabriella Fabbrocini et al.
SKIN APPENDAGE DISORDERS (2015)
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Roger B. Cohen
CANCER TREATMENT REVIEWS (2014)
Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients
Tanusree Paul et al.
EUROPEAN JOURNAL OF CANCER (2014)
Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
Makoto Tahara et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
Sewanti Limaye et al.
ORAL ONCOLOGY (2013)
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Beth Sherrill et al.
ONCOTARGETS AND THERAPY (2012)
Interrater reliability: the kappa statistic
Mary L. McHugh
BIOCHEMIA MEDICA (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPY OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Mark E. Sharafinski et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer
Daris Ferrari et al.
ANTI-CANCER DRUGS (2009)
Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapeutic agents and the skin: An update
Noushin Heidary et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a) and MTAP genes in head and neck sduamous cell carcinoma
MJ Worsham et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2006)
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications
Michel Zimmermann et al.
RADIATION ONCOLOGY (2006)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the eastern cooperative oncology group
MK Gibson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Squamous cell carcinomas of the head and neck
RJ Sanderson et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
分享论文
